Auxiliary pluripotency-associated genes and their contributions in the generation of induced pluripotent stem cells

Dey, Chandrima; Raina, Khyati; Thool, Madhuri; Adhikari, Poulomi; Haridhasapavalan, Krishna Kumar; Sundaravadivelu, Pradeep Kumar; Venkatesan, Vishalini; Gogoi, Ranadeep; Selvaraju, Sudhagar; Thummer, Rajkumar P.

doi:10.1016/b978-0-323-90059-1.00007-5

Cited by 6 publications

(3 citation statements)

References 330 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Takahashi and Yamanaka first reprogrammed human skin fibroblasts using retroviral vectors expressing the transcription factors OCT3/4, SOX2, KLF4, and c-MYC ( 15 ). Since then, multiple vectors expressing various types of transcription factors that can reprogram various cells have emerged rapidly with the aim of identifying more efficient and safer transfection methods ( 16 , 17 , 18 , 19 , 20 ). However, vectors are usually scavenged during host cell division, which may significantly reduce the pluripotency of iPSCs ( 21 , 22 ), or the persistence of vectors limits their potential applications for laboratory safety requirements ( 23 , 24 ).…”

Section: Resultsmentioning

confidence: 99%

Reprogramming and multi-lineage transdifferentiation attenuate the tumorigenicity of colorectal cancer cells

Guo,

Wang,

Pang

et al. 2024

Journal of Biological Chemistry

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

Reprogramming and multi-lineage transdifferentiation attenuate the tumorigenicity of colorectal cancer cells

Guo,

Wang,

Pang

et al. 2024

Journal of Biological Chemistry

View full text Add to dashboard Cite

“…Another group led by James Thomson later generated stable iPSCs using a partially different reprogramming factor cocktail consisting of Oct4, Sox2, Nanog, and Lin28 to reprogram human fibroblasts (Yu et al 2007 ). Since then, many genes (Dey et al 2022 ) and cell types (Ray et al 2021 ; Sundaravadivelu et al 2021 ) have been identified that play a crucial role in generating iPSCs efficiently. Various technological advancements have been made with an aim to prospectively generate clinical-grade iPSCs for future biomedical applications (Dey et al 2017 , 2021 ; Saha et al 2018a ; Haridhasapavalan et al 2019 , 2020 ; Borgohain et al 2019 ).…”

Section: A Brief Summary Of Crispr and Ipscsmentioning

confidence: 99%

CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics

Sen

Thummer

2022

Neurotox Res

Self Cite

View full text Add to dashboard Cite

Neurodegenerative diseases are prominent causes of pain, suffering, and death worldwide. Traditional approaches modelling neurodegenerative diseases are deficient, and therefore, improved strategies that effectively recapitulate the pathophysiological conditions of neurodegenerative diseases are the need of the hour. The generation of human-induced pluripotent stem cells (iPSCs) has transformed our ability to model neurodegenerative diseases in vitro and provide an unlimited source of cells (including desired neuronal cell types) for cell replacement therapy. Recently, CRISPR/Cas9-based genome editing has also been gaining popularity because of the flexibility they provide to generate and ablate disease phenotypes. In addition, the recent advancements in CRISPR/Cas9 technology enables researchers to seamlessly target and introduce precise modifications in the genomic DNA of different human cell lines, including iPSCs. CRISPR-iPSC-based disease modelling, therefore, allows scientists to recapitulate the pathological aspects of most neurodegenerative processes and investigate the role of pathological gene variants in healthy non-patient cell lines. This review outlines how iPSCs, CRISPR/Cas9, and CRISPR-iPSC-based approaches accelerate research on neurodegenerative diseases and take us closer to a cure for neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, Amyotrophic Lateral Sclerosis, and so forth.

show abstract

“…Fast forward to today, however, how to overcome the barriers in the process of somatic cell reprogramming is still a challenging issue and restrict the development of iPSCs in regenerative medicine (Arabaci et al, 2021; Ebrahimi, 2015; Haridhasapavalan et al, 2020). Many transcription factors, such as NANOG, LIN28, PBX1, and GLIS1, were found to enhance the efficiency by either combining with OSKM or replacing several of OSKM (Dey et al, 2022; Jiang et al, 2019; J. Yu et al, 2007; Li et al, 2020). As we can see, although some works have been made in finding transcription factors that can improve reprogramming efficiency, it is still important to look further for genes that may play an important role in inducing reprogramming.…”

Section: Introductionmentioning

confidence: 99%

LMCD1 facilitates the induction of pluripotency via cell proliferation, metabolism, and epithelial‐mesenchymal transition

Chen

Hou

et al. 2022

Cell Biology International

View full text Add to dashboard Cite

Somatic cell reprogramming was achieved by lentivirus mediated overexpression of four transcription factors called OSKM: OCT3/4, SOX2, KLF4, and c-MYC but it was not very efficient. Here, we reported that the transcription factor, LMCD1 (LIM and cysteine rich domains 1) together with OSKM can induce reprogramming of human dermal fibroblasts into induced pluripotent stem cells (iPSCs) more efficiently than OSKM alone. At the same time, the number of iPSCs clones were reduced when we knocked down LMCD1. Further study showed that LMCD1 can enhance the cell proliferation, the glycolytic capability, the epithelial-mesenchymal transition (EMT), and reduce the epigenetic barrier by upregulating epigenetic factors (EZH2, WDR5, BMI1, and KDM2B) in the early stage of reprogramming, making the cells more accessible to gain pluripotency. Additional research suggested that LMCD1 can not only inhibit the developmental gene GATA6, but also promote multiple signaling pathways, such as AKT and glycolysis, which are closely related to reprogramming efficiency. Therefore, we identified the novel function of the transcription factor LMCD1, which reduces the barriers of the reprogramming from somatic to pluripotent cells in several ways in the early stage of reprogramming.

show abstract

Auxiliary pluripotency-associated genes and their contributions in the generation of induced pluripotent stem cells

Cited by 6 publications

References 330 publications

Reprogramming and multi-lineage transdifferentiation attenuate the tumorigenicity of colorectal cancer cells

Reprogramming and multi-lineage transdifferentiation attenuate the tumorigenicity of colorectal cancer cells

CRISPR and iPSCs: Recent Developments and Future Perspectives in Neurodegenerative Disease Modelling, Research, and Therapeutics

LMCD1 facilitates the induction of pluripotency via cell proliferation, metabolism, and epithelial‐mesenchymal transition

Contact Info

Product

Resources

About